ArticleApplied biochemistry and biotechnology2026
Prognostic and Functional Role of HELLS in Prostate Cancer: Implications for Tumor Progression and Immune Microenvironment.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to explore the oncogenic role and clinical significance of Lymphoid-specific helicase (HELLS) in prostate cancer (PCa), with a particular focus on its correlation with immune infiltration. HELLS expression level in PCa tissues and cell lines was evaluated using immunohistochemistry, Western blot, quantitative real-time polymerase chain reaction, Cell Counting Kit−8, and Transwell assays. Bioinformatics analyses, including Gene Ontology/Kyoto Encyclopedia of Genes and Genomes and single-sample gene set enrichment analysis (ssGSEA), were performed to identify HELLS-related genes and explore their correlations with immune cell infiltration. HELLS expression was significantly higher in PCa tissues and cell lines (PC−3, DU145 and C4−2B) than in normal prostate tissues. Elevated HELLS expression was associated with adverse clinicopathological characteristics and poorer patient outcomes, including reduced overall survival, disease-specific survival, and progression-free interval. Furthermore, based on TCGA PCa cohort data revealed that HELLS levels were significantly linked to immune cell infiltration, particularly Th2 and Th17 cells. In vitro silencing of HELLS in PC−3 cells significantly suppressed cellular proliferation, migration, and invasion, providing preliminary evidence for its pro-tumor role in this subtype. HELLS represents a promising potential biomarker for PCa prognosis and a therapeutic target. Its correlation with immune cell infiltration underscores its relevance within the tumor microenvironment, though further validation in diverse models is required to confirm mechanistic insights.
Indexed as
Identifiers
41863575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.